<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004129</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000067357</org_study_id>
    <secondary_id>CMM-2</secondary_id>
    <secondary_id>NCI-V99-1575</secondary_id>
    <nct_id>NCT00004129</nct_id>
  </id_info>
  <brief_title>Phosphorus 32 in Treating Patients With Glioblastoma Multiforme</brief_title>
  <official_title>Phase I/II Study of Interstitial Colloidal 32P for the Treatment of Recurrent Malignant Central Nervous System Tumors and Primary Central Nervous System Tumors With Poor Prognostic Factors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Center for Molecular Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Radioactive drugs such as phosphorus 32 may be able to kill tumor cells.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of phosphorus 32 in&#xD;
      treating patients with glioblastoma multiforme.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the dosimetry toxicity of interstitial colloidal phosphorus P32 (C P32) in&#xD;
           patients with recurrent or poor prognosis grade 4 astrocytoma.&#xD;
&#xD;
        -  Determine the maximum tolerated dose of C P32 administered directly into the tumor of&#xD;
           these patients.&#xD;
&#xD;
        -  Determine the maximum tolerated fractionated dose of interstitial C P32 in these&#xD;
           patients.&#xD;
&#xD;
        -  Determine the therapeutic response rate to the acceptable single and fractionated doses&#xD;
           of C P32 in these patients.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study.&#xD;
&#xD;
      Patients receive interstitial colloidal phosphorus P32 (C P32) on day 0. Courses repeat every&#xD;
      4-6 weeks in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 3 patients receive escalating doses of C P32 until the maximum tolerated dose&#xD;
      (MTD) is determined. The MTD is defined the dose at which 2 of 3 patients experience&#xD;
      dose-limiting toxicity.&#xD;
&#xD;
      Patients are followed at 1, 2, 4, 6, 9, 15, and 24 weeks.&#xD;
&#xD;
      PROJECTED ACCRUAL: A minimum of 12 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 1999</start_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Brain and Central Nervous System Tumors</condition>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>brachytherapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>phosphorus P32</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically proven grade 4 astrocytoma (glioblastoma)&#xD;
&#xD;
               -  Failed external beam radiotherapy and/or surgery OR&#xD;
&#xD;
               -  Poor prognosis disease&#xD;
&#xD;
          -  No clinical evidence of metastatic disease within the CNS other than the primary tumor&#xD;
             site&#xD;
&#xD;
          -  Stereotactic biopsy or gross total excision with residual tumor&#xD;
&#xD;
          -  Lesion 3 to 5 cm in size&#xD;
&#xD;
          -  No spinal cord tumor(s)&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Karnofsky 70-100%&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  WBC at least 3,000/mm3&#xD;
&#xD;
          -  Neutrophil count at least 1,900/mm3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm3&#xD;
&#xD;
          -  Hemoglobin at least 9 g/dL (transfusion allowed)&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 1.5 mg/dL&#xD;
&#xD;
          -  BUN less than 25 mg/dL&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stanley E. Order, MD, ScD, FACR</last_name>
    <role>Study Chair</role>
    <affiliation>Center for Molecular Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Center for Molecular Medicine</name>
      <address>
        <city>Garden City</city>
        <state>New York</state>
        <zip>11530</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stanley E. Order, MD, ScD, FACR</last_name>
      <phone>516-222-5190</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2008</verification_date>
  <study_first_submitted>December 10, 1999</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>September 16, 2013</last_update_submitted>
  <last_update_submitted_qc>September 16, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 17, 2013</last_update_posted>
  <keyword>recurrent adult brain tumor</keyword>
  <keyword>adult glioblastoma</keyword>
  <keyword>adult giant cell glioblastoma</keyword>
  <keyword>adult gliosarcoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

